Abstract PD4-03: OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer-Reference-Cited by-同舟云学术

Abstract PD4-03: OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

Published:2020-02-14 Issue: Volume: Page:
ISSN:
Container-title:Poster Spotlight Session Abstracts
language:
Short-container-title:

Author:

Robson Mark,Im Seock-Ah,Senkus Elżbieta,Xu Binghe,Domchek Susan,Masuda Norikazu,Delaloge Suzette,Li Wei,Tung Nadine,Armstrong Anne,Bannister Wendy,Goessl Carsten,Allen Allison,Conte Pierfranco

Publisher

American Association for Cancer Research

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DNA damage targeted therapy for advanced breast cancer;Exploration of Targeted Anti-tumor Therapy;2024-06-25

2. Facing the conundrum: which first-line therapy should be used for patients with metastatic triple-negative breast cancer carrying germline BRCA mutation?;Exploration of Targeted Anti-tumor Therapy;2023-12-27

3. Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review;Cancer Treatment Reviews;2023-03

4. Therapy of BRCA-associated metastatic breast cancer. Efficacy and safety of talazoparib in the real-world clinical practice;Meditsinskiy sovet = Medical Council;2022-12-06

5. PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers;Expert Opinion on Investigational Drugs;2022-05-03